 | Up a level |
Journal Article
Michels, Sebastian Yves Friedrich, Scheffler, Matthias, Gardizi, Masyar, Christiaan, Marc, Bos, Allardt, Nogova, Lucia, Koenig, Katharine, Fassunke, Jana, Heydt, Carina, Michaela, Ihle, Kuenstlinger, Helen, Toepit, Karin, Ueckeroth, Frank, Albus, Kerstin, Serke, Monika Heidi, Randerath, Winfried, Engel-Riedel, Walburga, Merkelbach-Bruse, Sabine, Heukamp, Lukas Carl, Buettner, Reinhard and Wolf, Juergen (2014). Clinical and molecular characteristics of non-small cell lung cancer patients harboring PIK3CA mutations. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Nogova, Lucia, Gardizi, Masyar, Christiaan, Marc, Bos, Allardt, Scheffler, Matthias, Mattonet, Christian, Heukamp, Lukas Carl, Schildhaus, Hans-Ulrich, Fuhr, Uwe, Eberhardt, Wilfried, Reis, Henning, Wiesweg, Marcel, Schmid, Kurt Werner, Schoch, Gernot, Ko, Yon-Dschun, Serke, Monika Heidi, Schuler, Martin H., Buettner, Reinhard and Wolf, Juergen (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Scheffler, Matthias, Gardizi, Masyar, Christiaan, Marc, Bos, Allardt, Nogova, Lucia, Michels, Sebastian, Persigehl, Thorsten, Sos, Martin L., Dletlein, Felix, Zander, Thomas and Wolf, Juergen (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 mid RAD001 in stolid tumors and to determine the maximum tolerated dose (MTD) of the combination. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755